Media stories about ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ:BIB) have trended somewhat positive this week, Accern reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. ProShares Ultra Nasdaq Biotechnology ETF earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave headlines about the exchange traded fund an impact score of 44.0913516750635 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Shares of ProShares Ultra Nasdaq Biotechnology ETF (NASDAQ BIB) traded up $0.81 on Friday, reaching $61.54. The company’s stock had a trading volume of 238,800 shares, compared to its average volume of 208,101. ProShares Ultra Nasdaq Biotechnology ETF has a 52 week low of $40.22 and a 52 week high of $64.51.
TRADEMARK VIOLATION NOTICE: This piece was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/01/13/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-proshares-ultra-nasdaq-biotechnology-etf-bib-share-price.html.
ProShares Ultra Nasdaq Biotechnology ETF Company Profile
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period.
Receive News & Ratings for ProShares Ultra Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares Ultra Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.